{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:07:23Z","timestamp":1791176843628,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal de Gyn\u00e9cologie Obst\u00e9trique et Biologie de la Reproduction"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.jgyn.2007.11.019","type":"journal-article","created":{"date-parts":[[2008,1,11]],"date-time":"2008-01-11T11:03:15Z","timestamp":1200049395000},"page":"S155-S166","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S","title":["Vaccination contre le papillomavirus humain"],"prefix":"10.1016","volume":"37","author":[{"given":"J.-L.","family":"Brun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgyn.2007.11.019_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/JVI.67.1.315-322.1993","article-title":"Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins","volume":"67","author":"Hagensee","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.jgyn.2007.11.019_bib2","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1099\/0022-1317-75-8-2075","article-title":"Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera","volume":"75","author":"Rose","year":"1994","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jgyn.2007.11.019_bib3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen\u00a0? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jgyn.2007.11.019_bib4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions\u00a0: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jgyn.2007.11.019_bib5","first-page":"598","article-title":"Management of anogenital warts (condylomata acuminata)","volume":"11","author":"Von Krogh","year":"2001","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jgyn.2007.11.019_bib6","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18 L1 VLP vaccine formulated with the MPL\/aluminium salt combination (ASO4) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jgyn.2007.11.019_bib7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jnci\/93.4.284","article-title":"Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine","volume":"93","author":"Harro","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jgyn.2007.11.019_bib8","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"Proof of Principle Study Investigators. A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgyn.2007.11.019_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia\u00a0: a randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2007.11.019_bib10","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jgyn.2007.11.019_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgyn.2007.11.019_bib12","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18\u00a0: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jgyn.2007.11.019_bib13","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jgyn.2007.11.019_bib14","series-title":"Proceedings of the 2007 AACR Annual Meeting. Los Angeles","article-title":"Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16\/18 L1 VLP AS04 candidate vaccine","author":"Gall","year":"2007"},{"key":"10.1016\/j.jgyn.2007.11.019_bib15","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jgyn.2007.11.019_bib16","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgyn.2007.11.019_bib17","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60852-6","article-title":"Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials","volume":"369","year":"2007","journal-title":"Lancet"},{"issue":"18S","key":"10.1016\/j.jgyn.2007.11.019_bib18","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/jco.2007.25.18_suppl.3007","article-title":"Human papillomavirus (HPV) 16\/18 L1 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well-tolerated 18 months after vaccination in women up to age 55 years. Proceedings of the 2007 ASCO Annual Meeting","volume":"25","author":"Schwartz","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgyn.2007.11.019_bib19","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jgyn.2007.11.019_bib20","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jgyn.2007.11.019_bib21","series-title":"Proceedings of the 23rd international papillomavirus conference and clinical workshop. Prague","first-page":"8","article-title":"Gardasil\u00ae antibodies cross-neutralize pseudovirion infection of vaccine-related HPV type","author":"Smith","year":"2006"},{"key":"10.1016\/j.jgyn.2007.11.019_bib22","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.jgyn.2007.11.019_bib23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jgyn.2007.11.019_bib24","series-title":"Les connaissances, attitudes, croyances et comportements face au VIH\/sida en France","author":"Beltzer","year":"2005"},{"key":"10.1016\/j.jgyn.2007.11.019_bib25","first-page":"1","article-title":"Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002","volume":"23","author":"Abma","year":"2004","journal-title":"Vital Health Stat"},{"key":"10.1016\/j.jgyn.2007.11.019_bib26","unstructured":"Calendrier vaccinal 2006. Avis du Conseil sup\u00e9rieur d\u2019hygi\u00e8ne publique de France. Bull Epidemiol Hebd 2006;29\u201330:212\u20136."},{"key":"10.1016\/j.jgyn.2007.11.019_bib27","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.297.8.813","article-title":"Prevalence of HPV infection among females in the United States","volume":"297","author":"Dunne","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jgyn.2007.11.019_bib28","unstructured":"Comit\u00e9 Technique des Vaccinations et Conseil Sup\u00e9rieur d\u2019Hygi\u00e8ne Publique de France, section des maladies transmissibles. Rapport du groupe de travail sur la vaccination contre les papillomavirus. 23 mars 2007. www.sante.gouv.fr\/htm\/dossiers\/cshpf\/cs232.htm."},{"key":"10.1016\/j.jgyn.2007.11.019_bib29","unstructured":"Arr\u00eat\u00e9 du 5 juillet 2007 modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques remboursables aux assur\u00e9s sociaux. Journal Officiel de la R\u00e9publique fran\u00e7aise. \u00c9dition n\u00b0 0159. 11 juillet 2007."},{"key":"10.1016\/j.jgyn.2007.11.019_bib30","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1371\/journal.pmed.0030138","article-title":"Epidemiology of HPV16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses","volume":"3","author":"Barnabas","year":"2006","journal-title":"PLoS Med"},{"issue":"suppl","key":"10.1016\/j.jgyn.2007.11.019_bib31","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1086\/425271","article-title":"Role of herd immunity in determining the effect of vaccines against sexually transmitted disease","volume":"191","author":"Garnett","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgyn.2007.11.019_bib32","first-page":"3406","article-title":"A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV16 positive","volume":"6","author":"Muderspach","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jgyn.2007.11.019_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2515\/therapie:2005035","article-title":"Vaccination anti-papillomavirus humains","volume":"60","author":"Bourgault-Villada","year":"2005","journal-title":"Th\u00e9rapie"},{"key":"10.1016\/j.jgyn.2007.11.019_bib34","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00432-003-0463-5","article-title":"Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients","volume":"129","author":"Ferrara","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jgyn.2007.11.019_bib35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2007.04.038","article-title":"Heat shock fusion protein-based immunotherpay for treatment of cervical intraepithelial neoplasia III","volume":"106","author":"Einstein","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jgyn.2007.11.019_bib36","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.vaccine.2004.05.013","article-title":"Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX\u00ae adjuvant in women with cervical intraepithelial neoplasia","volume":"23","author":"Frazer","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.jgyn.2007.11.019_bib37","series-title":"Proceedings of the 23rd international papillomavirus conference and clinical workshop. Prague","first-page":"66","article-title":"Twelve month follow-up data of the HPV16 CIN2\/3 women having responded to Transgene's therapeutic vaccine TG4001","author":"Brun","year":"2006"},{"key":"10.1016\/j.jgyn.2007.11.019_bib38","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","article-title":"Regression of papilloma high-grade lesions (CIN2 and CIN3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine","volume":"13","author":"Garcia-Hernandez","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.jgyn.2007.11.019_bib39","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.AOG.0000110246.93627.17","article-title":"ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial","volume":"103","author":"Garcia","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jgyn.2007.11.019_bib40","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1158\/1078-0432.CCR-04-2599","article-title":"Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype","volume":"11","author":"Trimble","year":"2005","journal-title":"Clin Cancer Res"}],"container-title":["Journal de Gyn\u00e9cologie Obst\u00e9trique et Biologie de la Reproduction"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036823150700470X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036823150700470X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T13:35:34Z","timestamp":1588253734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036823150700470X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S036823150700470X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgyn.2007.11.019","relation":{},"ISSN":["0368-2315"],"issn-type":[{"value":"0368-2315","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}